Ultragenyx Pharmaceutical Inc. (RARE)
$37.82
Rating:
Recommendation:
Neutral
| Symbol | RARE |
|---|---|
| Price | $37.82 |
| Beta | 0.939 |
| Volume Avg. | 0.59M |
| Market Cap | 2.656B |
| Shares () | - |
| 52 Week Range | 33.36-85.53 |
| 1y Target Est | - |
| DCF Unlevered | RARE DCF -> | |
|---|---|---|
| DCF Levered | RARE LDCF -> | |
| ROE | -123.25% | Strong Sell |
| ROA | -45.77% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 338.43% | Strong Buy |
| P/E | -3.67 | Strong Sell |
| P/B | 7.50 | Strong Buy |
Latest RARE news
About
Download (Excel)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.